Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120268 | 0.85 | ALDH1A1 (0.60) | HRH3POLBTSHRMCHR1TP53 | |
| SCHEMBL4119648 | 0.84 | ALDH1A1 (0.58) | POLBTSHRTP53 | |
| SCHEMBL4107614 | 0.84 | CNR1 (0.71) | CNR1EPHX2HRH3POLBMCHR1 | |
| SCHEMBL4111628 | 0.84 | EPHX2 (0.53) | EPHX2HRH3TSHRMCHR1 | |
| SCHEMBL4123704 | 0.78 | DRD2 (0.53) | CNR1EPHX2HRH3TP53 | |
| SCHEMBL4107145 | 0.78 | CNR1 (0.60) | CNR1EPHX2TP53 | |
| SCHEMBL4113123 | 0.78 | CNR1 (0.60) | CNR1EPHX2TP53 | |
| SCHEMBL4115004 | 0.77 | CNR1 (0.59) | CNR1EPHX2POLBTSHRTP53 | |
| SCHEMBL4112231 | 0.77 | CNR1 (0.59) | CNR1EPHX2HRH3POLBTP53 | |
| SCHEMBL2478909 | 0.76 | HDAC1 (0.52) | EPHX2POLBTSHRMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | ACTIVE BIOTECH AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1711175-A1 | DIUREA DERIVATIVES | Active Biotech AB (SE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2005074919-A1 | DIUREA DERIVATIVES | ACTIVE BIOTECH AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118330-A1 | Diurea derivatives | IL2, CASP2, MAVS | CNR1 3201/4885EPHX2 1614/4885HRH3 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.